Prognostic Factors of Vogt-Koyanagi-Harada Disease in Singapore

被引:72
作者
Chee, Soon-Phaik [1 ,3 ,4 ]
Jap, Aliza [1 ,2 ]
Bacsal, Kristine [1 ]
机构
[1] Singapore Natl Eye Ctr, Singapore 168751, Singapore
[2] Chang Gen Hosp, Div Ophthalmol, Singapore, Singapore
[3] Singapore Eye Res Inst, Singapore, Singapore
[4] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore
关键词
INTRAVITREAL TRIAMCINOLONE; CHILDREN; THERAPY; FUNDUS;
D O I
10.1016/j.ajo.2008.07.044
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To determine prognostic factors of Vogt-Koyanagi-Harada disease (VKH). DESIGN: Retrospective noninterventional. METHODS: Chart review of VKH patients of Singapore National Eye Centre for age at onset (age), gender, race, presenting visual acuity (VA) and VA at one month after starting treatment, severity of inflammation, treatment regime, and hearing loss. Outcome measures were: VA, persistent inflammation, cataracts, glaucoma, macular lesions, chorioretinal degeneration, and vitiligo at three years after onset. RESULTS: There were 134 eyes of 67 patients. Majority were Chinese (n = 53, 79.1%) and female (n = 40, 59.7%). Median duration of follow-up was 9.1 years (range, 3.0 to 53.6 years). Median age was 42.3 years (range, 5.4 to 70.9 years). Main prognostic factors were VA at one month, age, and treatment regime. Good VA at one month was associated with greater likelihood of good VA at three years (odds ratio [OR], 43.9; P = .02), less persistent inflammation (OR, 0.5; P = .006), cataract (OR, 0.10; P = .01), and chorioretinal degeneration (OR, 0.2; P = .04). Older age was associated with higher likelihood of cataract (OR, 1.1; P =.02), chorioretinal degeneration (OR, 1.1; P = .03), and vitiligo (OR, 1.1; P = .004). Early treatment with high-dose systemic corticosteroids resulted in less persistent inflammation (OR, 0.2; P = .04). Late high corticosteroid treatment was associated with greater risk of cataract (OR, 9.6; P = .03). 0 CONCLUSION: Good VA at one month, younger age at onset, and early treatment with high-dose corticosteroids were associated with better outcomes. (Am J Ophthalmol 2009;147:154-161. (C) 2009 by Elsevier Inc. All rights reserved.)
引用
收藏
页码:154 / 161
页数:8
相关论文
共 21 条
[1]   Prognostic factors in Vogt-Koyanagi-Harada disease [J].
Al-Kharashi A.S. ;
Aldibhi H. ;
Al-Fraykh H. ;
Kangave D. ;
Abu El-Asrar A.M. .
International Ophthalmology, 2007, 27 (2-3) :201-210
[2]   Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome [J].
Andrade, RE ;
Muccioli, C ;
Farah, ME ;
Nussenblatt, RB ;
Belfort, R .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 137 (03) :572-574
[3]   VARIATIONS IN CLINICAL-FEATURES OF THE VOGT-KOYANAGI-HARADA-SYNDROME [J].
BENIZ, J ;
FORSTER, DJ ;
LEAN, JS ;
SMITH, RE ;
RAO, NA .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 1991, 11 (03) :275-280
[4]   Spectrum of Vogt-Koyanagi-Harada disease in Singapore [J].
Chee S.-P. ;
Jap A. ;
Bacsal K. .
International Ophthalmology, 2007, 27 (2-3) :137-142
[5]   Visual function in Vogt-Koyanagi-Harada patients [J].
Chee, SP ;
Luu, CD ;
Cheng, CL ;
Lim, WK ;
Jap, A .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2005, 243 (08) :785-790
[6]   SYMPATHETIC OPHTHALMIA AND VOGT-KOYANAGI-HARADA SYNDROME [J].
GOTO, H ;
RAO, NA .
INTERNATIONAL OPHTHALMOLOGY CLINICS, 1990, 30 (04) :279-285
[7]   Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome [J].
Karacorlu, M. ;
Karacorlu, S. Arf ;
Ozdemir, H. .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2006, 16 (03) :481-483
[8]   Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation [J].
Keino, H ;
Goto, H ;
Usui, M .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2002, 240 (10) :878-882
[9]   VOGT-KOYANAGI-HARADA SYNDROME [J].
MOORTHY, RS ;
INOMATA, H ;
RAO, NA .
SURVEY OF OPHTHALMOLOGY, 1995, 39 (04) :265-292
[10]  
OHNO S, 1988, JPN J OPHTHALMOL, V32, P334